You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A simple assay system for rapid detection of circulating tumor cells

    SBC: TELOVISION, LLC            Topic: NCI

    DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins

    SBC: LI-COR, Inc.            Topic: 100

    DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: 300

    DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Universal amplifier system for high-fidelity multi-modal biosignal recordings

    SBC: REFER2INPUT, LLC            Topic: 213

    DESCRIPTION provided by applicant The measurement monitoring and use of bioelectric signals has evolved from the measurement of the electrical activity of the heart to encompass tissues ranging from cardiac skeletal and smooth muscles to brain and peripheral nerve tissues Together with this development has been the evolution of specialized equipment to capture and interpret these minute sig ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Long life radio frequency surface plasma source

    SBC: MUONS INC            Topic: 30d

    The development of H- ion sources with highest performance is essential for the success of the next generation of high power proton accelerators. Project X at Fermilab needs a CW H- Ion Source that satisfies demanding performance specifications: 10 mA CW beam current with normalized transverse rms emittance 0.2 mm-mr, fast chopping capability, fast intensity variation, and high availability. Man ...

    STTR Phase I 2014 Department of Energy
  9. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government